Overall survival curves (A: all stages, n=4,635; C: stage I/II, n=2,475; E: stage III/IV, n=1,832) and lymphoma-related survival curves (B: all stages, n=4,066; D: stage I/II, n=2,188; F: stage III/IV, n=1,584) by age category among patients initially receiving R-CHOP. OS=overall survival; LRS=lymphoma-related survival; R-CHOP=rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.